Aurinia Pharmaceuticals Inc. - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Aurinia Pharmaceuticals Inc., a foreign private issuer, on January 3, 2017. The filing serves to report a material change and incorporates the report by reference into the company's Registration Statement on Form F-10 (File No. 333-206994). The document is signed by Dennis Bourgeault, Chief Financial Officer.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a cover sheet for a Material Change Report (Exhibit 99.1) rather than a financial statement.
Material Changes
The registrant reports a material change dated January 3, 2017, detailed in Exhibit 99.1. The specific nature of this change is not described in the cover text of the Form 6-K.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, or specific risk factors. These details are expected to be contained within the referenced Exhibit 99.1.
Key Facts for Investor Verification
- Verify the specific details of the Material Change Report (Exhibit 99.1) referenced in this filing.
- Confirm the status of the Registration Statement on Form F-10 (File No. 333-206994) into which this report is incorporated.
- Note that no financial performance data is included in this specific Form 6-K cover document.